Isoform-selective histone deacetylase inhibitors
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Histone deacetylase (HDAC) proteins are transcription regulators linked to cancer. As a result, multiple small molecule HDAC inhibitors are in various phases of clinical trials as anti-cancer drugs. The majority of HDAC inhibitors non-selectively influence the activities of eleven human HDAC isoforms, which are divided into distinct classes. This tutorial review focuses on the recent progress toward the identification of class-selective and isoform-selective HDAC inhibitors. The emerging trends suggest that subtle differences in the active sites of the HDAC isoforms can be exploited to dictate selectivity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Histone deacetylases (HDACs) are epigenetic regulators that modulate gene expression by removing acetyl groups from lysine residues on proteins, affecting processes like cell proliferation, differentiation, and development.504,505”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [504]
Citations
Cites
Epigenetic programming by maternal behavior
Weaver, I. C. G., Cervoni, N., Champagne, F. A., D'Alessio, A. C., Sharma, S., Seckl, J. R., Dymov, S., Szyf, M., & Meaney, M. J. (2004) · Nature Neuroscience · doi:10.1038/nn1276 · Cited by 6,177
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Protein kinases — the major drug targets of the twenty-first century?
Cohen, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd773 · Cited by 2,186
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714
Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456
Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0430973100 · Cited by 1,066
(2002) · PubMed · Cited by 732
Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors
Khan, N., Jeffers, M., Kumar, S., Hackett, C., Boldog, F., Khramtsov, N., Qian, X., Mills, E., Berghs, S. C., Carey, N., et al. (2008) · Biochemical Journal · doi:10.1042/bj20070779 · Cited by 713
Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases
Somoza, J. R., Skene, R. J., Katz, B. A., Mol, C., Ho, J. D., Jennings, A. J., Luong, C., Arvai, A., Buggy, J. J., Chi, E., et al. (2004) · Structure · doi:10.1016/j.str.2004.04.012 · Cited by 710
Research works printed but not linked: 1
- Furumai, 2002, Cancer Res., 62, 4916
Cited by
Items 101–200 of 396
HDACi: Cellular Effects, Opportunities for Restorative Dentistry
Duncan, H. F., Smith, A. J., Fleming, G. J. P., & Cooper, P. R. (2011) · Journal of Dental Research · doi:10.1177/0022034511406919 · Cited by 59
Targeting histone deacetylases for the treatment of disease
Lawless, M. W., Norris, S., O'Byrne, K. J., & Gray, S. G. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00571.x · Cited by 53
Hassan, M. M., Israelian, J., Nawar, N., Ganda, G., Manaswiyoungkul, P., Raouf, Y. S., Armstrong, D., Sedighi, A., Olaoye, O. O., Erdogan, F., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01025 · Cited by 41
Wambua, M. K., Nalawansha, D. A., Negmeldin, A. T., & Pflum, M. K. H. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401837e · Cited by 52
Self-citationStructure-activity relationships of HDAC8 inhibitors: Non-hydroxamates as anticancer agents
Amin, S. A., Adhikari, N., & Jha, T. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.03.001 · Cited by 53
Energy based pharmacophore mapping of HDAC inhibitors against class I HDAC enzymes
Kalyaanamoorthy, S., & Chen, Y. P. (2012) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2012.08.009 · Cited by 48
Boissinot, M., Inman, M., Hempshall, A., James, S. R., Gill, J. H., Selby, P., Bowen, D. T., Grigg, R., & Cockerill, P. N. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.07.002 · Cited by 47
Recent Advances in Cancer Therapeutics
Chessum, N. E. A., Jones, K., Pasqua, E., & Tucker, M. (2015) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2014.11.002 · Cited by 53
Lu, S., Wang, C., Ma, J., & Wang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1456030 · Cited by 56
A small molecule differentiation inducer increases insulin production by pancreatic β cells
Dioum, E. M., Osborne, J. K., Goetsch, S. C., Russell, J. L., Schneider, J. W., & Cobb, M. H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118526109 · Cited by 47
Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma
Mokhtari, R. B., Baluch, N., Tsui, M., Kumar, S., Homayouni, T. S., AITKEN, K. J., Das, B., Baruchel, S., & Yeger, H. (2017) · BMC Cancer · doi:10.1186/s12885-017-3126-7 · Cited by 47
Trivedi, P., Adhikari, N., Amin, S. A., Bobde, Y., Routholla, G., Jha, T., & Ghosh, B. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.105046 · Cited by 47
Zhang, I., Beus, M., Stochaj, U., Le, P. U., Zorc, B., Rajić, Z., Petrecca, K., & Maysinger, D. (2018) · Cell Death Discovery · doi:10.1038/s41420-018-0103-0 · Cited by 49
Colussi, C., Illi, B., Rosati, J. D., Spallotta, F., Farsetti, A., Grasselli, A., Mai, A., Capogrossi, M. C., & Gaetano, C. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.02.014 · Cited by 45
Hou, X., Du, J., Liu, R., Zhou, Y., Li, M., Xu, W., & Fang, H. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/ci500762z · Cited by 44
Bhansali, P. R., Hanigan, C. L., Casero, R. A., & Tillekeratne, L. M. V. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200432a · Cited by 43
Kalyaanamoorthy, S., & Chen, Y. P. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci200584f · Cited by 42
Role of histone deacetylases(HDACs) in progression and reversal of liver fibrosis
Li, X., Wu, X., Xu, T., Li, X., Yang, Y., Li, W., Huang, C., Meng, X., & Li, J. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.07.003 · Cited by 45
Multi-targeted HDAC Inhibitors as Anticancer Agents: Current Status and Future Prospective
Patel, V. K., Shirbhate, E., Tiwari, P., Kore, R., Veerasamy, R., Mishra, A., & Rajak, H. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220922105615 · Cited by 47
Improved Synthesis and Structural Reassignment of MC1568: A Class IIa Selective HDAC Inhibitor
Fleming, C. L., Ashton, T. D., Gaur, V., McGee, S. L., & Pfeffer, F. M. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401945k · Cited by 44
Vinken, M., Rop, E. D., Decrock, E., Vuyst, E. D., Leybaert, L., Vanhaecke, T., & Rogiers, V. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.08.002 · Cited by 42
Therapeutic Potential of Isoform Selective Hdac Inhibitors for the Treatment of Schizophrenia
Weïwer, M., Lewis, M. C., Wagner, F. F., & Holson, E. B. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.141 · Cited by 46
Liu, C., Zhang, Y., Li, J., Wang, Y., Ren, F., Zhou, Y., Wu, Y., Feng, Y., Zhou, Y., Su, F., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.620872 · Cited by 41
Li, S., Wang, F., Qu, Y., Chen, X., Gao, M., Yang, J., Zhang, D., Zhang, N., Li, W., & Liu, H. (2016) · Oncology Letters · doi:10.3892/ol.2016.5436 · Cited by 45
Giannini, G., Marzi, M., Pezzi, R., Brunetti, T., Battistuzzi, G., Marzo, M. D., Cabri, W., Vesci, L., & Pisano, C. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.02.029 · Cited by 41
Pramanik, S. D., Halder, A. K., Mukherjee, U., Kumar, D., Dey, Y. N., & Mogana, R. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.948217 · Cited by 47
Ganai, S. A. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.04.022 · Cited by 41
Rooker, D. R., & Buccella, D. (2015) · Chemical Science · doi:10.1039/c5sc02704g · Cited by 39
Pham‐The, H., Casañola‐Martín, G. M., Diéguez‐Santana, K., Nguyen-Hai, N., Ngoc, N. T., Vu-Duc, L., & Le‐Thi‐Thu, H. (2017) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2017.1294198 · Cited by 38
Uba, A. İ., & Yelekçi, K. (2017) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2017.1384402 · Cited by 43
Horne, W. S., Olsen, C. A., Beierle, J. M., Montero, A., & Ghadiri, M. R. (2009) · Angewandte Chemie · doi:10.1002/ange.200805900 · Cited by 40
Antibody drug conjugates (ADCs) charged with HDAC inhibitor for targeted epigenetic modulation
Cini, E., Faltoni, V., Petricci, E., Taddei, M., Salvini, L., Giannini, G., Vesci, L., Milazzo, F. M., Anastasi, A. M., Battistuzzi, G., et al. (2018) · Chemical Science · doi:10.1039/c7sc05266a · Cited by 43
Zhang, J., Li, L., Wu, W., Pan, T.-J., Yang, Z., & Yang, Y. (2018) · Medical Science Monitor · doi:10.12659/msm.912227 · Cited by 41
Discovery of HDAC6-Selective Inhibitor NN-390 with in Vitro Efficacy in Group 3 Medulloblastoma
Nawar, N., Bukhari, S., Adile, A., Suk, Y., Manaswiyoungkul, P., Toutah, K., Olaoye, O. O., Raouf, Y. S., Sedighi, A., Garcha, H. K., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01585 · Cited by 38
Aurones as histone deacetylase inhibitors: Identification of key features
Zwick, V., Chatzivasileiou, A. O., Deschamps, N., Roussaki, M., Simões‐Pires, C. A., Nurisso, A., Denis, I., Blanquart, C., Martinet, N., Carrupt, P., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.10.019 · Cited by 43
Evidence for the involvement of epigenetics in the progression of renal fibrogenesis
Tampe, B., & Zeisberg, M. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft361 · Cited by 38
Histone deacetylase 3 inhibits new tumor suppressor gene DTWD1 in gastric cancer.
Ma, Y., Yue, Y., Pan, M., Sun, J., Chu, J., Lin, X., Xu, W., Feng, L., Chen, Y., Chen, D., et al. (2015) · Europe PMC (PubMed Central) · Cited by 44
Zhao, W.-N., Ghosh, B., Tyler, M., Lalonde, J., Joseph, N. F., Kosaric, N., Fass, D. M., Tsai, L.-H., Mazitschek, R., & Haggarty, S. J. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00116 · Cited by 35
Bhagat, S. D., Singh, U., Mishra, R. K., & Srivastava, A. (2018) · ChemMedChem · doi:10.1002/cmdc.201800367 · Cited by 39
Bermúdez-Lugo, J. A., Pérez-González, O. A., Rosales‐Hernández, M. C., Ilizaliturri‐Flores, I., Trujillo-Ferrara, J. G., & Correa‐Basurto, J. (2011) · Journal of Molecular Modeling · doi:10.1007/s00894-011-1240-z · Cited by 36
Zhang, K., Liu, Z., Yao, Y., Qiu, Y., Li, F., Chen, D., Hamilton, D. J., Li, Z., & Jiang, S. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02161 · Cited by 35
Delayed and Prolonged Histone Hyperacetylation with a Selective HDAC1/HDAC2 Inhibitor
Methot, J. L., Hoffman, D. M., Witter, D. J., Stanton, M. G., Harrington, P., Hamblett, C., Siliphaivanh, P., Wilson, K., Hubbs, J., Heidebrecht, R., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4004233 · Cited by 31
Ghosh, B., Zhao, W., Reis, S. A., Patnaik, D., Fass, D. M., Tsai, L., Mazitschek, R., & Haggarty, S. J. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.01.022 · Cited by 38
Gurbani, S. S., Yoon, Y., Weinberg, B. D., Salgado, E., Press, R. H., Cordova, J. S., Ramesh, K. K., Liang, Z., Vega, J. E. V., Voloschin, A. D., et al. (2019) · Tomography · doi:10.18383/j.tom.2018.00031 · Cited by 35
Naturally Occurring Regulators of Histone Acetylation/Deacetylation
Folmer, F., Orlikova, B., Schnekenburger, M., Dicato, M. A., & Diederich, M. F. (2010) · Current Nutrition & Food Science · doi:10.2174/157340110790909581 · Cited by 37
Conformationally Locked Calixarene-Based Histone Deacetylase Inhibitors
Chini, M. G., Terracciano, S., Riccio, R., Bifulco, G., Ciao, R., Gaeta, C., Troisi, F., & Neri, P. (2010) · Organic Letters · doi:10.1021/ol102420b · Cited by 33
Marine Power on Cancer: Drugs, Lead Compounds, and Mechanisms
Wu, L., Ye, K., Jiang, S., & Zhou, G. (2021) · Marine Drugs · doi:10.3390/md19090488 · Cited by 36
Green, K. D., Biswas, T., Pang, A. H., Willby, M. J., Reed, M. S., Stuchlik, O., Pohl, J., Posey, J. E., Tsodikov, O. V., & Garneau‐Tsodikova, S. (2018) · Biochemistry · doi:10.1021/acs.biochem.7b01089 · Cited by 35
A steered molecular dynamics mediated hit discovery for histone deacetylases
Kalyaanamoorthy, S., & Chen, Y. P. (2013) · Physical Chemistry Chemical Physics · doi:10.1039/c3cp53511h · Cited by 32
Small-Molecule Chromatin-Modifying Agents: Therapeutic Applications
Mai, A. (2010) · Epigenomics · doi:10.2217/epi.10.7 · Cited by 35
Selective Photorelease of an Organometallic-Containing Enzyme Inhibitor
Leonidova, A., Mari, C., Aebersold, C., & Gasser, G. (2016) · Organometallics · doi:10.1021/acs.organomet.6b00029 · Cited by 38
MS-275 (Entinostat) Promotes Radio-Sensitivity in PAX3-FOXO1 Rhabdomyosarcoma Cells
Cassandri, M., Pomella, S., Rossetti, A., Petragnano, F., Milazzo, L., Vulcano, F., Camero, S., Codenotti, S., Cicchetti, F., Maggio, R., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910671 · Cited by 33
Sulfamides as novel histone deacetylase inhibitors
Wahhab, A., Smil, D. V., Ajamian, A., Allan, M., Chantigny, Y., Therrien, É., Nguyen, N. N. M., Manku, S., Leit, S. M., Rahil, J. F., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.11.081 · Cited by 31
Iranshahi, M., Chini, M. G., Masullo, M., Sahebkar, A., Javidnia, A., Yazdi, M. C., Pergola, C., Koeberle, A., Werz, O., Pìzza, C., et al. (2015) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b00700 · Cited by 31
Narita, K., 松原圭介, Itoh, J., Akiyama, Y., Dan, S., Yamori, T., Ito, A., Yoshida, M., & Katoh, T. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.05.031 · Cited by 34
Histone Deacetylase Inhibitors from Burkholderia thailandensis
Klausmeyer, P., Shipley, S. M., Zuck, K. M., & McCloud, T. G. (2011) · Journal of Natural Products · doi:10.1021/np200532d · Cited by 32
Design and synthesis of novel isoxazole-based HDAC inhibitors
Conti, P., Tamborini, L., Pinto, A., Solá, L., Ettari, R., Mercurio, C., & Micheli, C. D. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.06.035 · Cited by 30
Traore, M. D. M., Zwick, V., Simões‐Pires, C. A., Nurisso, A., Issa, M. E., Cuendet, M., Maynadier, M., Wein, S., Vial, H. J., Jamet, H., et al. (2017) · ACS Omega · doi:10.1021/acsomega.6b00481 · Cited by 31
Almaliti, J., Al-Hamashi, A. A., Negmeldin, A. T., Hanigan, C. L., Perera, L., Pflum, M. K. H., Casero, R. A., & Tillekeratne, L. M. V. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01271 · Cited by 30
Self-citationElek, G. Z., Koppel, K., Zubrytski, D. M., Konrad, N., Järving, I., Lopp, M., & Kananovich, D. G. (2019) · Organic Letters · doi:10.1021/acs.orglett.9b03305 · Cited by 32
Choi, S. E., & Pflum, M. K. H. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.09.093 · Cited by 32
Self-citationThe Role of DNMT and HDACs in the Fetal Programming of Hypertension by Glucocorticoids
LaMothe, J. M., Khurana, S., Tharmalingam, S., Williamson, C., Byrne, C. J., Khaper, N., Mercier, S., & Tai, T. C. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/5751768 · Cited by 29
Yang, Y., Liu, K., Liang, Y., Chen, Y., Chen, Y., & Gong, Y. (2015) · PubMed Central · Cited by 27
Post-translational lysine ac(et)ylation in health, ageing and disease
Blasl, A., Schulze, S., Qin, C., Graf, L. G., Vogt, R., & Lammers, M. (2021) · Biological Chemistry · doi:10.1515/hsz-2021-0139 · Cited by 31
Isolation, synthesis and medicinal chemistry of biphenyl analogs – A review
Singh, S., Geetha, P., & Ramajayam, R. (2023) · Results in Chemistry · doi:10.1016/j.rechem.2023.101135 · Cited by 30
Padige, G., Negmeldin, A. T., & Pflum, M. K. H. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115598118 · Cited by 28
Self-citationTerracciano, S., Micco, S. D., Bifulco, G., Gallinari, P., Riccio, R., & Bruno, I. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.03.022 · Cited by 30
Choi, S. E., Weerasinghe, S. V. W., & Pflum, M. K. H. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.08.027 · Cited by 33
Self-citationA highly HDAC6-selective inhibitor acts as a fluorescent probe
Ho, Y.-H., Wang, K.-J., Hung, P.-Y., Cheng, Y., Liu, J.-R., Fung, S.-T., Liang, P., Chern, J., & Yu, C. (2018) · Organic & Biomolecular Chemistry · doi:10.1039/c8ob00966j · Cited by 29
Narita, K., Fukui, Y., Sano, Y., Yamori, T., Ito, A., Yoshida, M., & Katoh, T. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.12.023 · Cited by 28
Sixto‐López, Y., Gómez-Vidal, J. A., & Correa‐Basurto, J. (2014) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-014-0976-1 · Cited by 26
Mai, A., Valente, S., Nebbioso, A., Simeoni, S., Ragno, R., Massa, S., Brosch, G., Bellis, F. D., Manzo, F., & Altucci, L. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.09.002 · Cited by 28
Epigenetic approaches for bipolar disorder drug discovery
Peedicayil, J. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.922537 · Cited by 26
Neuroprotective effects of histone deacetylase inhibitors in brain ischemia
Ziemka‐Nałęcz, M., & Zalewska, T. (2014) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2014-2001 · Cited by 28
Ganai, S. A. (2016) · Pharmaceutical Biology · doi:10.3109/13880209.2015.1135966 · Cited by 26
Nikhil, K. L., Korge, S., & Kramer, A. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3000792 · Cited by 25
PROTAC chemical probes for histone deacetylase enzymes
Patel, U., Smalley, J. P., & Hodgkinson, J. T. (2023) · RSC Chemical Biology · doi:10.1039/d3cb00105a · Cited by 26
Human genetics of diabetic vascular complications
Tang, Z., FANG, Z., & Zhou, L. (2013) · Journal of Genetics · doi:10.1007/s12041-013-0288-1 · Cited by 23
Chavan, S. P., Khairnar, L. B., Pawar, K. P., Chavan, P. N., & Kawale, S. A. (2015) · RSC Advances · doi:10.1039/c5ra06429e · Cited by 24
Perspectives on the Discovery of Small-Molecule Modulators for Epigenetic Processes
Lu, Q., Quinn, A. M., Patel, M. P., Semus, S. F., Graves, A. P., Bandyopadhyay, D., Pope, A. J., & Thrall, S. H. (2012) · SLAS DISCOVERY · doi:10.1177/1087057112437763 · Cited by 24
Highly fluorescent and HDAC6 selective scriptaid analogues
Fleming, C. L., Natoli, A. L., Schreuders, J., Devlin, M. G., Yoganantharajah, P., Gibert, Y., Leslie, K. G., New, E. J., Ashton, T. D., & Pfeffer, F. M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.020 · Cited by 24
Sirous, H., Campiani, G., Brogi, S., Calderone, V., & Chemi, G. (2020) · Molecules · doi:10.3390/molecules25081952 · Cited by 26
Synthesis and evaluation of lysine derived sulfamides as histone deacetylase inhibitors
Manku, S., Allan, M., Nguyen, N. N. M., Ajamian, A., Rodrigue, J., Therrien, É., Wang, J., Guo, T., Rahil, J. F., Petschner, A. J., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.02.075 · Cited by 24
Kasotakis, G., Kintsurashvili, E., Galvan, M. D., Graham, C., Purves, J. T., Agarwal, S., Corcoran, D. L., Sullenger, B. A., Palmer, S. M., & Remick, D. G. (2019) · Shock · doi:10.1097/shk.0000000000001372 · Cited by 22
The development and potential clinical utility of biomarkers for HDAC inhibitors
Shi, B. (2013) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2013.v7.4.129 · Cited by 22
Huang, L.-Y., Hsu, D., & Pears, C. J. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab154 · Cited by 23
Nutrition, Epigenetic Mechanisms, and Human Disease
Maulik, N., & Maulik, G. (2010) · CRC Press eBooks · doi:10.1201/b10449 · Cited by 83
A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold
Kemp, M. M., Wang, Q., Fuller, J. H., West, N. H., Martínez, N. M., Morse, E. M., Weïwer, M., Schreiber, S. L., Bradner, J. E., & Koehler, A. N. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.05.098 · Cited by 24
Feng, T., Wang, H., Su, H. L., Lu, H., Yu, L., Zhang, X., Sun, H., & You, Q. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.06.009 · Cited by 23
Polycystic kidney disease and therapeutic approaches
Park, E.-Y., Woo, Y.-M., & Park, J.-H. (2011) · BMB Reports · doi:10.5483/bmbrep.2011.44.6.359 · Cited by 21
Anticancer RuII and RhIII Piano‐Stool Complexes that are Histone Deacetylase Inhibitors
Cross, J. M., Blower, T. R., Gallagher, N., Gill, J. H., Rockley, K. L., & Walton, J. W. (2016) · ChemPlusChem · doi:10.1002/cplu.201600413 · Cited by 22
Hirata, Y., Sasaki, T., Kanki, H., Choong, C.-J., Nishiyama, K., Kubo, G., Hotei, A., Taniguchi, M., Mochizuki, H., & Uesato, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-19664-9 · Cited by 20
Evolution of Slow-Binding Inhibitors Targeting Histone Deacetylase Isoforms
Mukherjee, A., Zamani, F., & Suzuki, T. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01160 · Cited by 23
Advances in dual-targeting inhibitors of HDAC6 for cancer treatment
Gu, Z., Lin, S., Yu, J., Jin, F., Zhang, Q., Xia, K., Chen, L., Li, Y., & He, B. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116571 · Cited by 24
Yoo, J., Kim, S., Son, D., Seo, H., Baek, S. Y., Maeng, C.-Y., Lee, C., Kim, I. S., Jung, Y. H., Lee, S., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.046 · Cited by 21
Chemical optogenetic modulation of inflammation and immunity
Parasar, B., & Chang, P. V. (2016) · Chemical Science · doi:10.1039/c6sc03702j · Cited by 21
Creating zinc monkey wrenches in the treatment of epigenetic disorders
Kalin, J. H., Butler, K. V., & Kozikowski, A. P. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.05.007 · Cited by 21
Pathogenic bone loss in rheumatoid arthritis: mechanisms and therapeutic approaches
Cantley, M. D., Smith, M., & Haynes, D. R. (2009) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.09.42 · Cited by 22
Design, Synthesis, and biological evaluation of HDAC6 inhibitors based on Cap modification strategy
Li, X., Liu, X., Wang, S., Shi, X., Lü, M., Hao, X., Fu, Y., Zhang, Y., Jia, Q., & He, D. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105874 · Cited by 20
Franci, G., Casalino, L., Petraglia, F., Miceli, M., Menafra, R., Radic-Sarikas, B., Tarallo, V., Vitale, M., Scarfò, M., Pòcsfalvi, G., et al. (2013) · Biology Open · doi:10.1242/bio.20135587 · Cited by 19
Metadata
- Authors
- Bieliauskas, A. V., & Pflum, M. K. H.
- Affiliations
- Wayne State University (US)
- Corresponding author
- Pflum, Mary Kay H.
- ORCID
- Pflum, Mary Kay H.
- Venue
- Chemical Society Reviews
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2008
- Volume
- 37
- Issue
- 7
- Pages
- 1402
- ISSN
- 0306-0012 (ISSN-L)
- 1460-4744
- PMC
- PMC2593472
- OpenAlex
- W2124258829
- Cited by
- 350
- References
- 59
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 15 · 2023: 16 · 2022: 10 · 2021: 12 · 2020: 21 · 2019: 20 · 2018: 19 · 2017: 16 · 2016: 21 · 2015: 21 · 2014: 27 · 2013: 22 · 2012: 22
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Chemical Society Reviews (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute of General Medical Sciences (GM 067657, R01GM067657)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- histone deacetylase inhibitors, HDAC isoforms, isoform selectivity, cancer therapy, small molecule inhibitors, transcriptional regulation
- MeSH terms
- Vorinostat, Antineoplastic Agents, Binding Sites, Enzyme Inhibitors, Histone Deacetylases, Humans, Hydroxamic Acids, Tumor Cells, Cultured, Drug Design, Protein Isoforms, Cell Proliferation, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.